<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) are <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> which can be difficult to control with conventional therapies </plain></SENT>
<SENT sid="1" pm="."><plain>A greater understanding of their pathophysiology has led to new therapies that target specific molecules of the inflammatory cascade </plain></SENT>
<SENT sid="2" pm="."><plain>Three anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) monoclonal antibodies have been developed </plain></SENT>
<SENT sid="3" pm="."><plain>Infliximab and adalimumab can induce clinical response and sustained remission in CD </plain></SENT>
<SENT sid="4" pm="."><plain>Infliximab is also effective in UC </plain></SENT>
<SENT sid="5" pm="."><plain>Certolizumab pegol gives good short-term results but long-term efficacy has yet to be determined in other clinical trials </plain></SENT>
<SENT sid="6" pm="."><plain>Therapies that target leucocyte trafficking (anti-integrins) have also been developed and are associated with good clinical response in CD </plain></SENT>
<SENT sid="7" pm="."><plain>Natalizumab (anti-α4 integrin antibody) is associated with important side effects and is not used anymore in gastroenterology in Europe but is still used in the USA </plain></SENT>
<SENT sid="8" pm="."><plain>Vedolizumab (MLN0002), an anti-α4β7 integrin antibody, has a good efficacy and safety profile </plain></SENT>
<SENT sid="9" pm="."><plain>Monoclonal antibodies targeting other cytokines are also under development </plain></SENT>
<SENT sid="10" pm="."><plain>For example, ustekinumab (CNTO 1275) inhibits interleukins 12 and 23 </plain></SENT>
<SENT sid="11" pm="."><plain>It is associated with a good clinical response in CD </plain></SENT>
</text></document>